Headquartered in Tarrytown, NY·Fiscal year ends December·NASDAQ: REGN·regeneron.com
About Regeneron
Regeneron Pharmaceuticals is a biotechnology company that invents, develops, manufactures and commercializes antibody and genetic medicines for serious diseases. Its areas include eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological and hematologic conditions, infectious diseases and rare diseases.
Revenue comes from three main sources:
- **Net product sales of medicines it records itself:** EYLEA HD and EYLEA in the U.S., global Libtayo, U.S. Praluent, Evkeeza, Lynozyfic and others.
- **Collaboration revenue:** largely its share of profits from Sanofi-recorded global sales of Dupixent and Kevzara, plus Bayer's ex-U.S. sales of EYLEA HD and EYLEA.
- **Other revenue:** including royalties on ex-U.S. Praluent.
In October 2026, Regeneron expanded its Sanofi antibody alliance to add four next-generation, long-acting immunology antibodies. It received a $1.0 billion up-front payment and is eligible for up to $7.0 billion in milestones, with equal cost and profit sharing.
The company has about 50 clinical-stage candidates. Recent approvals include Pasatru (garetosmab) for FOP. Late-stage programs span multiple myeloma, lymphoma, anticoagulation (Factor XI antibodies), obesity, MASH, POTS and myasthenia gravis. Its research draws on proprietary platforms such as VelociSuite and the Regeneron Genetics Center. Regeneron also supplies the U.S. government with Inmazeb for Ebola preparedness, and returns capital through buybacks and a quarterly dividend. Updated
51 stocks printed fresh 52-week highs this week, and the leadership is energy plus big biotech: Cheniere cleared its prior peak by 11.7%, with Regeneron, Eli Lilly and Gilead all stretching more than 8% past theirs.
New 52-week high$927.89+8.9% vs prior high · 2026-09-02
Regeneron's Q3 earnings beat lifted it to a fresh 52-week high of $927.89, clearing the September 2 peak by 8.9%. That single jump erases months of range-bound trading in the biotech.
Intel closed down 29.27%, the widest single-session move across 380 priority names. Regeneron led the other direction, with chip and optics names filling out the downside.
Intel opened down 29%, a one-day drop of a size this name almost never posts, while the top of the board belongs entirely to pharma, led by Regeneron. Four of the five biggest decliners fell by double digits.
Dupixent sales jumped 34.8% to $6.36 billion, beating expectations and lifting full-year guidance. Management is already spending the windfall, expanding the Regeneron alliance to protect earnings through Dupixent's eventual loss of exclusivity.
Collaboration revenue jumped 68% to $2.72 billion on record Dupixent sales, with both lines beating expectations. Full-year non-GAAP gross margin guidance moved to roughly 86%.
A 4.89% slide to $729.05 takes roughly $3.6 billion off the biotech's market value in one session. Moves this size are rare for a $73.7 billion name, and the close is what matters now.
Cramer pushes back on index-fund supremacy, calling the absolutist version of it wrong
Still recommends 50% of savings in an S&P 500 fund as a hedge against your own mistakes
Argues the S&P holds far fewer than 500 good stocks, so you buy the bad with the good
Caller questions on portfolio structure for young investors, 529 plans, and retirement vs. mad money
Put half in an index fund as insurance, the other half in individual names you have actually done the homework on. Cramer's case is that an S&P 500 fund gives you 8% to 10% a year and mediocrity alongside the winners, which is why he says it will not make you rich on its own.
Regeneron (NASDAQ:REGN | REGN Price Prediction) shares rose 13.55% in Friday’s session, trading at $929.69 as of 9:45 AM ET on Oct 30, 2026. For a biotech worth roughly $94.03 billion, a…
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has…
Regeneron (NASDAQ:REGN | REGN Price Prediction) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter. I think that…
Pre-Market Stock Futures: Futures are trading mixed, but the Nasdaq is down sharply Thursday morning as worries about AI overspending continue to emerge. Wall Street’s worst fears materialized yesterday, as the Consumer…
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing…
While Wall Street piles into AI darlings, Michael Burry is quietly loading up on call options in three stocks the market left for dead, and his biggest bets carry a very specific…
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the…
FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave…
If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading…
Pre-Market Stock Futures: Futures are trading lower after a spectacular week came to an abrupt end Friday, as all the major indices were absolutely hammered. Voices across financial media were busy pointing out…
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi had one line on the February 26, 2026 earnings call that deserves attention beyond the headline numbers: his company just put the first IRF5-directed therapy in…
Pre-Market Stock Futures: Futures are trading lower as we prepare to finally end what has been one of the most volatile weeks in recent memory, with oil hitting its highest level since…
Most ETF names tell you what they own. COWG tells you what it believes in. Pacer US Large Cap Cash Cows Growth Leaders ETF (NYSEARCA:COWG) screens for large-cap US companies generating strong…
Pre-Market Stock Futures: Futures are trading lower on Wednesday after an ADP report showing job losses, following a stellar day across Wall Street on Tuesday. All of the major indices finished the…
Regeneron Pharmaceuticals is a biotechnology company that invents, develops, manufactures and commercializes antibody and genetic medicines for serious diseases.
What is the REGN stock price target?
24/7 Wall St.'s 12-month price target for REGN is $1,019.96, rated Buy. The Wall Street consensus target is $977.93. REGN price prediction →
